AXON 10-Q Quarterly Reports

Axon Enterprise, Inc. reported strong revenue growth of 33.7% to $807.3 million for the first quarter of 2026 compared to the prior year period. This top-line expansion was driven by robust performance across both its Connected Devices segment (up 32.8%) and Software and Services segment (up 34.9%). The company successfully transitioned from an operating loss in the prior year's quarter to an operating income of $29.2 million. Net income also saw a significant increase, rising to $169.3 million from $88.0 million in the same quarter last year, with diluted EPS growing to $2.05 from $1.08. The company made a substantial strategic acquisition of Carbyne Ltd. for $549.7 million, funded by existing cash and investments, which contributed to a significant decrease in cash and cash equivalents. While gross margins saw a slight compression due to tariffs and a higher mix of Platform Solutions revenue, the overall financial performance demonstrates continued strong execution and market demand for Axon's integrated technology solutions.

Axon Enterprise, Inc. (AXON) reported its financial results for the period ending September 30, 2025. The company experienced a significant increase in net sales, up 30.6% year-over-year for the third quarter, reaching $710.6 million. This growth was driven by strong performance in both its Connected Devices segment (up 23.6%) and its Software and Services segment (up 41.1%). However, the company reported a net loss of $2.2 million for the quarter, a reversal from the $67.0 million net income in the prior year period. This shift was influenced by increased operating expenses, particularly in Research & Development and Selling, General & Administrative, and a higher effective tax rate, partly due to the enactment of the 'One Big Beautiful Bill Act' (OBBBA) impacting R&D tax credits. Despite the quarterly net loss, the year-to-date (nine months ended September 30, 2025) performance shows a net income of $121.9 million, albeit lower than the $241.9 million in the same period last year. The company's balance sheet reflects a robust increase in cash and cash equivalents to $1.4 billion from $454.8 million, supported by strong financing activities including the issuance of $1.75 billion in Senior Notes and proceeds from an at-the-market equity offering. Management believes current liquidity sources are sufficient to meet anticipated cash requirements for at least the next 12 months.

Axon Enterprise, Inc. reported strong revenue growth for the second quarter of 2025, with net sales increasing by 32.8% year-over-year to $668.5 million. This growth was driven by robust performance in both the Connected Devices segment (up 28.6%) and the Software and Services segment (up 38.8%). Despite the top-line growth, the company reported a net loss from operations of $1.0 million for the quarter, a decrease from an income of $33.8 million in the prior year, primarily due to a significant increase in operating expenses, particularly in selling, general, and administrative costs driven by higher stock-based compensation and increased headcount. Financially, Axon bolstered its liquidity position significantly, with cash and cash equivalents increasing by $160.7 million to $615.5 million, and total available-for-sale investments growing by $1.1 billion to $1.5 billion, largely following the issuance of $1.75 billion in Senior Notes in March 2025. The company also experienced a substantial increase in financing cash flows due to these note issuances and ATM equity offerings. While revenue growth is positive, investors should monitor the increasing operating expenses and the impact of stock-based compensation, alongside the company's substantial debt load.

Axon Enterprise, Inc. (AXON) reported a strong top-line performance in its first quarter of 2025, with net sales increasing by 31.3% year-over-year to $603.6 million. This growth was driven by robust performance in both the Connected Devices and Software & Services segments. Despite the revenue increase, the company reported a net loss from operations of $8.8 million, a shift from income in the prior year, largely due to significant increases in operating expenses, particularly in selling, general, and administrative (SG&A) and research and development (R&D), driven by higher stock-based compensation and headcount expansion. The company also highlighted substantial gains from strategic investments ($167.3 million) which contributed significantly to its net income of $88.0 million.

Axon Enterprise, Inc. reported robust revenue growth for the third quarter and first nine months of 2024, with total net sales reaching $544.3 million and $1.5 billion respectively. This represents significant year-over-year increases of 31.7% and 33.4%, driven by strong performance in both the TASER and Software & Sensors segments. The company saw particular strength in TASER devices and cartridges, alongside continued growth in its cloud-based Axon Evidence and services. Despite the revenue surge, income from operations decreased year-over-year for both periods, primarily due to a substantial increase in operating expenses, notably higher stock-based compensation and R&D investments. Financially, Axon ended the quarter with a strong liquidity position, holding $695.1 million in cash and cash equivalents. The company also reported a significant increase in goodwill and intangible assets, largely due to the acquisition of Fusus, LLC. Additionally, Axon announced a major acquisition of Dedrone Holdings, Inc. in October 2024, signaling continued strategic expansion. While profitability metrics were impacted by increased expenses, the overall financial health and growth trajectory remain positive, supported by a substantial remaining performance obligation backlog of $7.7 billion.

Axon Enterprise, Inc. (AXON) reported strong revenue growth in its Form 10-Q for the period ending June 30, 2024. Total net sales increased by 34.6% year-over-year to $504.1 million for the quarter, and by 34.4% to $964.8 million for the six-month period. This growth was driven by both the TASER segment (up 27.6% quarterly) and the Software and Sensors segment (up 39.5% quarterly), with notable increases in TASER devices, cartridges, and Axon Body Cameras and Accessories. The company also saw a significant rise in its recurring revenue from cloud services. Despite robust top-line growth, operating income decreased year-over-year for both the quarter ($32.9 million vs. $40.3 million) and the six-month period ($49.2 million vs. $56.9 million). This was primarily attributed to increased operating expenses, particularly higher stock-based compensation and R&D investments, as well as amortization of acquired intangibles. The company's gross margin percentage also saw a slight decrease, impacted by these factors, although adjusted gross margin (excluding stock-based compensation and amortization) showed improvement, particularly in the Software and Sensors segment. Significant strategic investments and business acquisitions, including the acquisition of Fusus and the pending acquisition of Dedrone, are noted as key drivers of future growth and integration efforts.

Axon Enterprise, Inc. reported strong revenue growth in the first quarter of 2024, with net sales increasing by 34.3% year-over-year to $460.7 million. This growth was driven by robust performance in both the Software and Sensors segment (up 35.1%) and the TASER segment (up 33.1%), with notable contributions from Axon Evidence and Cloud Services, Axon Body Cameras and Accessories, and TASER devices. Despite significant revenue growth, operating income slightly decreased to $16.3 million from $16.6 million in the prior year, primarily due to increased operating expenses, including higher stock-based compensation and professional services related to acquisitions. However, net income saw a substantial increase of 195.1% to $133.2 million, largely influenced by significant gains from strategic investments and the Fusus acquisition. The company also announced a definitive agreement to acquire Dedrone Holdings, Inc. for approximately $400 million, further expanding its offerings in airspace security.

Axon Enterprise, Inc. (AXON) reported strong revenue growth in the third quarter and first nine months of 2023, driven by increases in both its TASER and Software and Sensors segments. Net sales for the quarter reached $413.6 million, a 32.7% increase year-over-year, while the nine-month total reached $1.1 billion, up 32.5%. This growth was fueled by robust demand for Axon Evidence and cloud services, Axon Body Cameras, and Axon Fleet Systems, alongside steady performance in TASER devices and cartridges. The company demonstrated improved operational efficiency, with income from operations rising significantly to $55.1 million for the quarter and $112.0 million for the nine months, compared to the prior year periods. While gross margin percentage saw a slight dip due to the ramp-up of new products like TASER 10 and increased costs in certain hardware and professional services, the overall dollar increase in gross margin was substantial. The company also managed its operating expenses effectively, with SG&A and R&D expenses growing at a slower pace than revenue, indicating good cost control as the company scales.

Axon Enterprise, Inc. (AXON) reported strong top-line growth in its second quarter of 2023, with net sales increasing by 31.2% year-over-year to $374.6 million. This growth was driven by a significant increase in both the TASER and Software and Sensors segments. The TASER segment saw a 13.9% rise, largely due to the new TASER 10 device, while the Software and Sensors segment experienced robust growth of 46.8%, fueled by strong demand for Axon Evidence and Cloud Services and Axon Fleet Systems. Despite the revenue surge, net income saw a substantial decrease to $12.4 million from $51.0 million in the prior year's quarter. This decline was primarily due to a significant non-cash unrealized impairment loss of $71.9 million related to a strategic investment. However, excluding this impairment, the company's operational performance showed resilience, with income from operations more than doubling year-over-year. The company also highlighted substantial future contracted revenue of $5.2 billion, indicating strong future revenue potential.

Axon Enterprise, Inc. reported strong revenue growth in the first quarter of 2023, with total net sales increasing by 33.8% year-over-year to $343.0 million. This growth was driven by robust performance in both the Software and Sensors segment (+46.9%) and the TASER segment (+17.4%). The Software and Sensors segment, in particular, saw significant boosts from Axon Evidence and Cloud Services, as well as Axon Fleet Systems. Despite the impressive revenue increase, net income decreased to $45.1 million from $54.9 million in the prior year, primarily due to a notable increase in operating expenses, particularly in sales, general, and administrative (SG&A) and research and development (R&D), which rose by 29.3% and 46.5% respectively. This increase in expenses was largely attributed to higher headcount, increased stock-based compensation, and higher salaries and benefits. The company ended the quarter with a healthy cash and cash equivalents balance of $263.4 million, though this was a decrease from the prior quarter. Axon also highlighted its substantial remaining performance obligations of approximately $4.8 billion, providing visibility into future contracted revenues. While the company faces ongoing risks related to supply chain, litigation, and macroeconomic conditions, its strategic investments in cloud-based solutions and continued expansion in the public safety technology market position it for sustained growth.

Axon Enterprise, Inc. reported strong revenue growth in the third quarter of 2022, with net sales increasing by 34.4% year-over-year to $311.8 million. This growth was primarily driven by the Software and Sensors segment, which saw a 51.0% increase in net sales, and continued strength in the TASER segment, particularly with the TASER 7 device. The company also achieved significant year-over-year improvement in profitability, with income from operations rising substantially to $32.1 million from $2.9 million in the prior year quarter. This profitability surge was aided by a significant decrease in stock-based compensation expense. For the nine-month period ended September 30, 2022, net sales grew by 32.2% to $853.8 million, and the company transitioned from a net loss of $46.5 million in the prior year to a net income of $118.0 million. A substantial portion of this improvement is attributable to a significant decrease in stock-based compensation expense. The company ended the quarter with a healthy liquidity position, characterized by $147.7 million in cash and cash equivalents and a strong backlog of future contracted revenue amounting to $3.73 billion, providing good visibility into future revenue streams.

Axon Enterprise, Inc. reported strong revenue growth in the second quarter of 2022, with total net sales reaching $285.6 million, a 30.5% increase year-over-year. This growth was primarily driven by the Software and Sensors segment, which saw a 41.2% surge, and robust performance in the TASER segment, up 20.5%. The company also achieved significant profitability, reporting net income of $51.0 million, a substantial turnaround from the net loss of $47.1 million in the prior year period. This improvement was largely due to a significant decrease in stock-based compensation expenses, coupled with strong revenue growth and effective cost management. Looking ahead, Axon revised its full-year 2022 revenue guidance upward to a range of $1.07 billion to $1.12 billion. The company continues to invest in its future, with projected capital expenditures of $80 million to $90 million. Despite increased costs in areas like freight and labor impacting gross margins, Axon's strategic focus on its growing software and services offerings, coupled with the strong demand for its TASER products, positions it well for continued expansion. Investors should note the significant unrealized gains from strategic investments which boosted net income this quarter, a factor that may not be recurring.

Axon Enterprise, Inc. (AXON) reported strong revenue growth in the first quarter of 2022, with net sales reaching $256.4 million, a 31.5% increase year-over-year, driven by significant expansion in the Software and Sensors segment (+48.0%) and continued growth in the TASER segment (+15.5%). The company achieved profitability with a net income of $54.9 million, a substantial improvement from a net loss of $47.9 million in the prior year's quarter. This turnaround was supported by a significant decrease in operating expenses, primarily due to lower stock-based compensation compared to the prior year, and increased revenue. The company has provided an optimistic revenue outlook for the full year 2022, projecting between $1.05 billion to $1.1 billion. Despite increased costs in areas like freight and labor, Axon is managing its gross margins, which stood at 60.7% for the quarter. The balance sheet remains strong with $386.4 million in cash and cash equivalents, and the company anticipates sufficient liquidity to meet its operational and capital expenditure needs.

Axon Enterprise, Inc. reported strong top-line growth for the third quarter and first nine months of 2021, with net sales increasing by 39.4% and 42.0%, respectively, compared to the prior year periods. This growth was driven by robust demand across both the TASER and Software and Sensors segments, with particular strength in the new TASER 7 devices and cloud-based Axon Evidence services. The company's strategic shift towards a subscription model is progressing, indicated by a significant increase in future contracted revenues to $2.39 billion. Financially, the company reported a significant swing to net income of $48.5 million for the third quarter of 2021, a substantial improvement from a net loss of $0.9 million in the prior year period. This turnaround was partly due to a substantial income tax benefit of $51.2 million. However, the nine-month period still resulted in a net loss of $46.5 million, influenced by a significant increase in operating expenses, particularly stock-based compensation related to performance awards. The company maintained a strong liquidity position with $281.7 million in cash and cash equivalents.

Axon Enterprise, Inc. reported strong top-line growth for the second quarter of 2021, with net sales increasing by 54.9% year-over-year to $218.8 million. This growth was driven by robust performance in both the TASER and Software & Sensors segments, with significant contributions from cartridge sales, the TASER 7 device, and expanded Axon Evidence and cloud services adoption. Despite the substantial revenue increase, the company reported a net loss of $47.1 million for the quarter, a wider loss compared to the prior year's $30.8 million. This was largely due to a significant increase in operating expenses, particularly stock-based compensation, which rose substantially due to updated estimates for performance-based awards. However, the company's financial position remains solid with $266.4 million in cash and cash equivalents and a strong overall contracted revenue backlog of $2.04 billion, indicating positive future revenue potential.

Axon Enterprise, Inc. (AXON) reported its first-quarter 2021 financial results, showing significant top-line growth driven by strong performance in both its TASER and Software and Sensors segments. Total net sales increased by 32.5% year-over-year to $195.0 million. The Software and Sensors segment, in particular, saw a 34.7% increase in net sales, highlighting the growing adoption of its cloud-based solutions and connected devices. Despite robust revenue growth, the company reported a net loss of $47.9 million for the quarter, a significant shift from a net income of $4.1 million in the prior year. This was largely driven by a substantial increase in operating expenses, primarily due to higher stock-based compensation expenses related to performance awards and increased investments in research and development and sales, general, and administrative functions to support future growth. The company maintains a strong liquidity position with $154.8 million in cash and cash equivalents and a clear outlook for the full year with projected revenues between $780 million and $820 million.

Axon Enterprise, Inc. reported significant revenue growth for the nine months ended September 30, 2020, up 26.7% year-over-year to $454.9 million. This growth was primarily driven by its Software and Sensors segment, which saw a 38.9% increase in net sales, highlighting the continued adoption of cloud-based solutions and new hardware like the Axon Body 3. Despite revenue expansion, the company experienced a net loss of $27.6 million for the nine-month period, a notable decrease from the $13.3 million net income in the prior year. This was largely influenced by a substantial increase in operating expenses, particularly stock-based compensation related to executive performance awards and increased legal expenses associated with FTC litigation. The balance sheet shows robust growth in current assets, including a significant increase in short-term investments and inventory. The company ended the period with $176 million in cash and cash equivalents, and a strong liquidity position. The balance of future contracted revenues remains substantial at $1.51 billion, providing a degree of revenue visibility, with expected recognition over the next 5-7 years. Investors should note the ongoing investments in research and development and the strategic shift towards subscription-based models. Key areas of focus for investors include the substantial increase in stock-based compensation, the material impact of the FTC litigation, and the ongoing investment in growth initiatives. While the revenue trajectory is positive, the profitability is being impacted by these significant expense items. The company's substantial future contracted revenue provides a positive outlook, but close monitoring of expense management and litigation outcomes will be crucial.

Axon Enterprise, Inc. reported its second-quarter 2020 financial results, showcasing robust revenue growth driven by strong performance in both its TASER and Software and Sensors segments. Net sales increased by 25.7% year-over-year to $141.3 million. However, the company reported a net loss of $30.8 million for the quarter, a significant shift from the $0.7 million net income in the prior year's quarter. This loss was largely influenced by a substantial increase in stock-based compensation expense, primarily related to performance awards, and increased legal expenses associated with the FTC litigation. Despite the net loss, the company highlighted a healthy increase in gross margin to 62.4% and a strong liquidity position with $319.3 million in cash and cash equivalents. The company's strategic shift towards a subscription-based model continues, with significant future contracted revenues totaling approximately $1.34 billion. Management expressed confidence in their ability to navigate the COVID-19 pandemic due to supply chain diversification and proactive measures. Key growth drivers include the new TASER 7 devices and cartridges, alongside continued expansion in cloud-based evidence management and body camera solutions.

Axon Enterprise, Inc. (AXON) reported a solid increase in net sales for the first quarter of 2020, reaching $147.2 million, a 27.1% increase year-over-year, driven by strong performance in both the TASER and Software & Sensors segments. Despite this top-line growth, the company experienced a net loss from operations of $0.8 million, a shift from income in the prior year, attributed to increased operating expenses, particularly in sales, general, and administrative (SG&A) functions, including a significant rise in stock-based compensation expense and litigation costs. Net income for the quarter was $4.1 million. The company highlighted its proactive measures and strong liquidity position in response to the COVID-19 pandemic, including operational adjustments and supply chain resilience, while noting potential impacts on customer budgets and collections. The company continues its strategic shift towards a subscription-based model, which is reflected in the growth of recurring Axon Cloud revenue and the increasing backlog of future contracted revenue ($1.27 billion). While inventory levels increased, reflecting preparation for demand, the company maintained a strong cash position of $156.5 million at the end of the quarter. Investors should monitor the impact of increased operating expenses and the ongoing FTC investigation.

Axon Enterprise, Inc. reported strong revenue growth in the third quarter of 2019, with net sales increasing by 24.8% year-over-year to $130.8 million. This growth was primarily driven by the Software and Sensors segment, which saw a 43.5% increase in net sales, fueled by higher adoption of cloud services and devices like Axon Body and Axon Fleet. The TASER segment also contributed positively with a 12.7% increase, though gross margins were compressed due to the rollout of the new TASER 7 device and associated trade-in credits. While the company reported an increase in net income to $6.1 million for the quarter, year-to-date net income saw a significant decrease to $13.3 million compared to $27.1 million in the same period last year, largely due to increased operating expenses, including substantial investments in R&D and SG&A to support future growth. The company ended the quarter with a healthy liquidity position, holding $204.1 million in cash, cash equivalents, and restricted cash. Despite the increase in operating expenses and a strategic shift towards subscription models, Axon maintains a positive outlook, projecting full-year 2019 revenue between $500 million and $510 million. Investors should monitor the impact of new product introductions on gross margins and the continued growth trajectory of the Software and Sensors segment, as well as the effective management of operating expenses.

Axon Enterprise, Inc. reported $112.4 million in net sales for the second quarter of 2019, a 13.2% increase year-over-year. Despite revenue growth, the company experienced a net loss of $1.3 million from operations, compared to an income of $5.3 million in the prior year's comparable period. This decline in operational profitability was attributed to increased cost of sales and investments in research and development and sales, general, and administrative functions to support growth. Significant R&D investment is ongoing, particularly in the Software and Sensors segment, indicating a strategic focus on expanding its cloud-connected device platform. The company's balance sheet shows total assets of $746.4 million as of June 30, 2019, with a notable increase in contract assets and inventory. Cash reserves decreased by $129.7 million, largely due to net purchases of investments. The company is strategically shifting towards a subscription-based model for its products, aiming to align with municipal budgeting cycles and enhance recurring revenue streams. This transition, along with the rollout of new products like the TASER 7, impacted short-term margins but is expected to drive long-term revenue growth.

Axon Enterprise, Inc. (AXON) reported its first-quarter 2019 results, showcasing strong revenue growth driven by its Software and Sensors segment, which increased by 33.8% year-over-year. This segment's performance was bolstered by significant growth in Axon Evidence and cloud services, along with extended warranties. While overall net sales grew 14.4% to $115.8 million, the company experienced a notable decrease in income from operations, falling to $2.7 million from $13.6 million in the prior year's quarter. This decline is attributed to increased cost of sales and higher operating expenses, particularly in research and development and sales, general, and administrative functions, as the company invests in future growth. The introduction of the new TASER 7 device also contributed to higher initial production costs. Despite the reduction in operating income, Axon's balance sheet remains robust, with cash and cash equivalents standing at $223.6 million. The company has strategically shifted towards a subscription model for its products, which is expected to improve recurring revenue and customer engagement over the long term, although it impacts near-term liquidity. Management remains optimistic about the full-year outlook, projecting revenues between $485 million and $495 million, signaling continued expansion despite the short-term margin pressures.

Axon Enterprise, Inc. (AXON) demonstrated significant financial strength in the third quarter of 2018, with total net sales reaching $104.8 million, a 16.1% increase year-over-year. This growth was largely driven by a substantial 33.5% surge in the Software and Sensors segment, particularly in Axon Evidence and cloud services, alongside a more modest 7.2% increase in the TASER Weapons segment. The company's strategic shift towards recurring revenue models is evident, with 53% of consolidated revenues coming from multi-element, multi-year contracts. This indicates a successful transition towards a more predictable revenue stream. Financially, Axon reported a net income of $5.7 million for the quarter, a significant improvement from $0.4 million in the prior year, leading to diluted EPS of $0.10. The balance sheet shows a robust increase in cash and cash equivalents to $324.4 million, largely due to a successful follow-on equity offering that raised $234.0 million in net proceeds. This strong liquidity position, coupled with strategic investments in R&D and a growing recurring revenue base, positions Axon for continued growth and market leadership in public safety technology.

Axon Enterprise, Inc. reported strong growth in its second quarter of 2018, with total net sales increasing by 24.6% to $99.2 million compared to the prior year quarter. This growth was driven by robust performance in both its TASER Weapons segment, up 14.4%, and its Software and Sensors segment, which saw an impressive 45.0% increase. The company's strategic shift towards subscription-based revenue models is gaining traction, with a significant portion of sales now coming from contracts with multiple performance obligations. Net income more than tripled year-over-year to $8.5 million, reflecting improved gross margins and operational efficiencies, although operating expenses, particularly R&D, also increased as the company continues to invest in innovation and expansion. The balance sheet shows a significant increase in cash and cash equivalents to $307.5 million, largely due to proceeds from a follow-on equity offering in May 2018. The company also reported an increase in goodwill and intangible assets, indicating strategic acquisitions or business development activities. While the company faces ongoing litigation, management believes it will not materially impact financial condition. The company is also addressing a previously identified material weakness in internal controls related to its UK subsidiary through remediation efforts.

Axon Enterprise, Inc. reported strong performance in its first quarter of 2018, with net sales increasing by 27.7% to $101.2 million year-over-year. This growth was primarily driven by a significant 74.7% increase in the Software and Sensors segment, largely due to the widespread adoption of its Evidence.com cloud-based evidence management system and on-officer camera solutions. The TASER Weapons segment also showed steady growth of 10.1%. The company's strategic shift towards recurring revenue models is evident, with a substantial portion of revenue now coming from multi-year contracts. Profitability improved significantly, with net income rising to $12.9 million, or $0.24 per diluted share, compared to $4.6 million, or $0.09 per diluted share, in the prior year's quarter. This expansion in earnings was supported by an increase in gross margin to 63.7% and a reduction in operating expenses as a percentage of net sales. The company also benefited from adopting new accounting standards (Topic 606), which positively impacted its reported revenue and equity. Axon ended the quarter with a healthy cash position, indicating solid financial footing for future growth.

Axon Enterprise, Inc. (AXON) reported solid revenue growth in the third quarter and the first nine months of 2017, driven by strong performance in both its TASER Weapons and Software and Sensors segments. Net sales increased by 25.6% year-over-year for the third quarter and 33.8% for the first nine months. The Software and Sensors segment showed particularly robust growth, with net sales up 62.8% in Q3 and 88.8% year-to-date, largely due to the increasing adoption of on-officer cameras and the Evidence.com platform. Despite revenue growth, the company experienced a significant increase in operating expenses, especially in Research and Development (R&D), which nearly doubled year-over-year for the quarter as Axon continues to invest in product innovation and expansion of its cloud-connected device platform. This increased investment, coupled with higher cost of sales and strategic discounting in the Software and Sensors segment, led to a decrease in gross margin percentage and a significant drop in operating income for the quarter. For the nine-month period, net income declined by 33.6% year-over-year. The company is actively managing its liquidity, with substantial cash, cash equivalents, and investments. However, operating activities used cash for the first nine months of 2017, primarily due to increased accounts receivable and inventory buildup, partially offset by significant increases in deferred revenue. Axon is also addressing material weaknesses in its internal controls over financial reporting, with remediation efforts underway.

Axon Enterprise, Inc. (AXON) reported strong top-line growth in its second quarter and first six months of 2017, driven by significant increases in both its TASER Weapons and Software and Sensors segments. Net sales for the second quarter of 2017 rose by 35.5% to $79.6 million, with the Software and Sensors segment nearly doubling its revenue, up 101.4% to $26.6 million. This growth was fueled by increased adoption of on-officer cameras, related technologies, and Evidence.com services, alongside continued strength in TASER weapons and cartridge sales. While revenue growth was robust, the company experienced a decrease in net income to $2.3 million for the quarter and $6.9 million for the six months, compared to $3.7 million and $7.1 million in the prior year periods, respectively. This was largely due to an increase in cost of goods sold and services delivered, particularly within the Software and Sensors segment, and a significant rise in research and development expenses, reflecting ongoing investment in new product development. The company is also actively working to remediate identified material weaknesses in internal controls over financial reporting, particularly in revenue recognition and income tax accounting, with expectations for completion by year-end 2017.

Axon Enterprise, Inc. (AXON) reported a strong first quarter for 2017, with net sales increasing by 42.7% year-over-year to $79.2 million. This growth was primarily driven by a significant surge in the Software and Sensors segment, which saw sales jump by 122.5% to $21.6 million, fueled by the increasing adoption of on-officer cameras and the Evidence.com platform. The TASER Weapons segment also showed robust growth, up 25.8% to $57.7 million, supported by strong cartridge sales and the positive impact of Smart Weapons approval in the UK. Despite the impressive top-line growth, the cost of products sold and services delivered increased at a faster rate (64.1%) than net sales, leading to a decrease in gross margin percentage from 66.5% to 61.4%. This was particularly noticeable in the Software and Sensors segment, where hardware gross margins declined due to higher discounting and service margins were impacted by data migration costs. However, the company managed operating expenses effectively, with Sales, General & Administrative expenses growing slower than revenue, resulting in a slight increase in Net Income to $4.6 million, or $0.09 per share.

Axon Enterprise, Inc. (formerly TASER International, Inc.) reported a strong financial performance for the nine months ended September 30, 2016, with net sales increasing by 31.2% to $186.2 million compared to the same period in 2015. This growth was driven by robust performance in both the TASER Weapons segment (+24.7%) and the rapidly expanding Axon segment (+60.0%). The Axon segment, which includes body cameras and Evidence.com, saw significant revenue increases, particularly from Evidence.com services which grew by 145.0%. Despite increased operating expenses, especially in Sales, General & Administrative (SG&A) which rose 61.6% primarily due to investments in sales and marketing for the Axon segment, the company maintained a healthy gross margin of 64.9% for the nine-month period. Financially, the company ended the period with $102.5 million in cash, cash equivalents, and investments. However, net income decreased by $3.9 million to $11.0 million for the nine-month period, largely impacted by increased operating expenses and a higher effective tax rate. The company also actively repurchased stock, spending $33.7 million in the first nine months of 2016. Management is focused on continued growth in the Axon segment and managing operational complexities, as indicated by the remediation efforts for identified material weaknesses in internal controls over financial reporting.

TASER International, Inc. (now Axon Enterprise, Inc.) reported solid top-line growth in the second quarter of 2016, with net sales increasing by 25.8% year-over-year to $58.8 million. This growth was primarily driven by a significant 48.7% increase in the Axon segment's net sales, signaling strong market adoption of their integrated hardware and software solutions, including on-officer cameras and Evidence.com. While the TASER Weapons segment also saw a 20.4% increase in sales, the Axon segment's rapid expansion suggests a successful strategic pivot towards broader law enforcement technology solutions. Despite revenue growth, profitability metrics show a mixed picture. Gross margin decreased slightly year-over-year, influenced by increased discounting in the TASER Weapons segment and a slight rise in cost of sales in the Axon segment. Furthermore, Sales, General, and Administrative (SG&A) expenses increased substantially, particularly within the Axon segment, due to investments in sales and marketing to support expansion. Consequently, net income for the quarter declined by approximately 40% to $3.7 million, or $0.07 per diluted share, compared to $6.1 million, or $0.11 per diluted share, in the prior year period. Investors should monitor the increasing SG&A as a percentage of sales and the continued growth trajectory of the Axon segment as key indicators for future profitability.

Axon Enterprise, Inc. (formerly TASER International, Inc.) reported a net sales increase of 24.1% to $55.5 million for the first quarter of 2016 compared to the prior year, driven by strong performance in both its TASER Weapons segment (up 19.5%) and its Axon segment (up 51.0%). The Axon segment's growth was particularly notable, fueled by a significant increase in Evidence.com recurring revenues and strong bookings for new products, despite a temporary dip in recognized camera revenue due to the introduction of the Axon Body 2. While gross margins remained stable year-over-year at 66.5%, operating expenses saw a substantial increase, primarily in Sales, General & Administrative (SG&A) and Research & Development (R&D) expenses. This increase is attributed to investments in expanding sales teams, product development for the growing Axon segment, and increased marketing efforts. Consequently, net income decreased to $3.5 million ($0.06 per diluted share) from $7.2 million ($0.13 per diluted share) in the prior year's quarter, reflecting the higher operating expenses. The company also repurchased approximately $9.0 million of its common stock under a new $50 million repurchase program. Financially, the company maintained a healthy liquidity position with $114.1 million in cash, cash equivalents, and investments at quarter-end, and no outstanding borrowings on its $10 million credit line. Despite the decrease in net income, the growth in net sales and bookings, particularly in the burgeoning Axon segment, indicates positive momentum for the company's strategic expansion into digital evidence management solutions.

Axon Enterprise, Inc. (formerly TASER International, Inc.) reported strong growth in its Axon segment, which includes body cameras and evidence management software, with net sales increasing by over 150% year-over-year for the third quarter of 2015. This growth was driven by increased adoption of Axon cameras and Evidence.com subscriptions. Conversely, the TASER Weapons segment saw a slight year-over-year decline in net sales, primarily due to the timing of larger sales transactions and a decrease in sales of the legacy TASER X26 CEW. Overall net sales for the company increased by 13.6% in the third quarter. The company's profitability was impacted by increased operating expenses, particularly in sales, general, and administrative (SG&A) and research and development (R&D), largely due to investments in the growing Axon segment. This led to a significant decrease in net income for the quarter compared to the prior year. Despite these investments, the company maintained a healthy cash position and positive cash flow from operations.

TASER International, Inc. (AXON) demonstrated robust top-line growth in the second quarter of 2015, with net sales increasing by 25.7% year-over-year to $46.7 million. This growth was driven by strong performance in both the TASER Weapons segment (+15.8%) and a significant surge in the Axon segment (+97.5%), indicating successful market adoption of their integrated hardware and software solutions for law enforcement. The company also showed improved profitability, with gross margin increasing to 65.8% and net income rising by 57.1% to $6.1 million. This was achieved despite an increase in R&D spending, particularly in the Axon segment, reflecting the company's investment in future growth. Management highlighted increased adoption of the TASER X26P and X2 smart weapons, alongside continued strong demand for Axon on-officer cameras and the Evidence.com platform as key drivers for the quarter's financial performance.

Axon Enterprise, Inc. (formerly TASER International, Inc.) reported a strong first quarter for 2015, demonstrating significant top-line growth and improved profitability. Net sales increased by 23.7% year-over-year to $44.8 million, driven by robust performance in both its TASER Weapons segment (up 18.1%) and the rapidly growing AXON segment (up 73.1%). The AXON segment, encompassing cameras and EVIDENCE.com, showed particular strength with substantial increases in sales of AXON solutions and EVIDENCE.com subscriptions. The company also achieved a significant improvement in gross margins, rising to 66.7% from 61.4% in the prior year, attributed to increased sales leverage and improved efficiency. This, combined with a more favorable mix of sales towards higher-margin products and services, contributed to a substantial increase in net income, which more than doubled to $7.2 million, or $0.13 per diluted share, from $3.4 million, or $0.06 per diluted share, in the first quarter of 2014. The company's balance sheet remains healthy with a significant cash position and no significant debt.

TASER International, Inc. (now Axon Enterprise, Inc.) reported strong growth in its third quarter of 2014, with net sales increasing by 26.0% year-over-year to $44.3 million. This revenue growth was primarily driven by significant increases in sales of its TASER X26P Smart Weapon and continued adoption of its EVIDENCE.com and AXON camera solutions. The company also saw a notable expansion in its EVIDENCE.com & Video segment, with revenue up 21.5% and bookings for AXON and EVIDENCE.com products surging significantly. Profitability also improved, with Net Income rising by 47.8% to $7.6 million, or $0.14 per diluted share. This was supported by a stronger gross margin of 64.7% and a decrease in Selling, General, and Administrative (SG&A) expenses as a percentage of sales, despite increased investment in Research and Development (R&D) for the EVIDENCE.com platform. The company's balance sheet remains solid, with $38.6 million in cash and cash equivalents, and it is actively managing its capital through a stock repurchase program.

TASER International, Inc. (now Axon Enterprise, Inc.) reported mixed financial results for the quarter ended June 30, 2014. While net sales increased by 15.5% year-over-year to $37.2 million, driven by strong performance in the TASER X26P Smart Weapon and the EVIDENCE.com & Video segment, net income decreased by 12.9% to $3.9 million. This decline in profitability was attributed to a significant increase in operating expenses, particularly in research and development (up 73.4%) and sales, general, and administrative (up 23.8%), largely due to investments in the EVIDENCE.com and video technology platform. Despite the dip in net income, the company maintained a healthy gross margin of 62.4%, indicating strong pricing power and operational efficiency in its core TASER Weapons segment. The company also continued its share repurchase program, acquiring $19.6 million in common stock during the quarter. Management expressed confidence in the company's ability to finance its operations and strategic initiatives through operating cash flow and its existing credit facility. The strategic shift towards investing heavily in the EVIDENCE.com & Video segment, while impacting short-term profitability, signals a long-term growth strategy aimed at expanding beyond traditional conducted electrical weapons.

TASER International, Inc. (now Axon Enterprise, Inc.) reported solid revenue growth in the first quarter of 2014, with net sales increasing by 18.9% year-over-year to $36.2 million. This growth was primarily driven by strong performance in the TASER Weapons segment, notably the TASER X26P Smart Weapon, and significant expansion in the EVIDENCE.com & Video segment, which saw a 52.6% increase in net sales. The company also experienced a substantial increase in international sales, representing 29.3% of total net sales, up from 10.3% in the prior year. Net income saw a modest increase to $3.4 million, or $0.06 per diluted share. The company ended the quarter with a healthy cash position of $45.1 million, demonstrating strong liquidity.

TASER International, Inc. (now Axon Enterprise, Inc.) reported a strong increase in net sales for the third quarter and the first nine months of 2013, driven by the successful adoption of its newer TASER X26P and X2 conducted electrical weapons (CEWs) and growth in its EVIDENCE.com & Video segment. The company saw a significant rise in gross margin due to increased sales volume and improved pricing, while managing cost of goods sold effectively. Despite increased sales, general, and administrative expenses, largely attributed to investments in sales and marketing and higher litigation defense costs, the company achieved substantial net income growth. Operating cash flow remained robust, though slightly decreased year-over-year due to increased investment in short-term investments and a significant stock repurchase program. The company ended the period with a healthy cash balance and no outstanding borrowings on its line of credit, indicating a solid liquidity position.

TASER International, Inc. (now Axon Enterprise, Inc.) reported a solid increase in net sales for the second quarter of 2013, driven by the successful adoption of its new TASER X26P conducted electrical weapon (CEW) and growth in its Video segment, which includes AXON products and EVIDENCE.com. The company demonstrated improved gross margins and operational efficiency, despite an increase in sales, general, and administrative (SG&A) expenses primarily due to strategic hires and litigation costs. While cash and cash equivalents decreased due to a significant stock repurchase program and investment activities, operating cash flow remained healthy, and the company maintained a strong liquidity position with ample available borrowing under its credit facility. Overall, the report indicates positive sales momentum and improving operational performance, though investors should monitor the impact of rising SG&A expenses and ongoing litigation. The company's strategic focus on new product adoption and its expanding Video segment are key drivers for future growth.

Axon Enterprise, Inc. (formerly TASER International, Inc.) reported solid revenue growth in the first quarter of 2013, with net sales increasing by 18.7% year-over-year to $30.4 million. This growth was primarily driven by strong adoption of the new TASER X2 and X26P conducted electrical weapons (CEWs), alongside continued momentum in the emerging Video segment which includes AXON cameras and EVIDENCE.com. While gross margins improved to 60.6% due to sales leverage and efficiencies in the Video segment, operating income saw a decline of 18.6% to $5.3 million. This was largely due to a significant increase in Sales, General, and Administrative (SG&A) expenses, up 26.6%, driven by strategic hires and increased investment in sales and marketing. Despite the increase in operating expenses, the company maintained a healthy cash position, ending the quarter with $38.6 million in cash and cash equivalents, and initiated a $25 million share repurchase program.

Axon Enterprise, Inc. (formerly TASER International, Inc.) reported a strong third quarter in 2012, demonstrating significant year-over-year growth in both revenue and net income. Net sales increased by 18.0% to $28.8 million, driven by robust demand for their TASER X2 Electronic Control Device (ECD) and increased cartridge sales. The company also saw substantial growth in its emerging Video segment, with sales nearly doubling. Profitability improved considerably, with gross margin expanding to 58.4% from 53.7% in the prior year's quarter, attributable to manufacturing efficiencies and a favorable product mix. Net income surged by 223.7% to $3.7 million, or $0.07 per share. The company's balance sheet remains healthy, with a solid cash position and positive operating cash flow of $23.3 million for the first nine months of the year. However, investors should note the ongoing litigation expenses and the company's stock repurchase program, which utilized $20 million in cash during the period.

TASER International, Inc. (now Axon Enterprise, Inc.) reported a significant turnaround in its financial performance for the quarter ended June 30, 2012, compared to the same period in the prior year. The company achieved a net income of $3.4 million, a substantial improvement from a net loss of $2.3 million in Q2 2011. This positive shift was driven by a robust increase in net sales, up 33.1% to $28.2 million, primarily fueled by the strong adoption of its TASER X2 conducted energy device and growth in its Video segment, including AXON on-officer cameras and EVIDENCE.com services. Furthermore, the company demonstrated improved operational efficiency, with a decrease in Sales, General & Administrative (SG&A) expenses as a percentage of net sales and a gross margin increase to 58.5%. The company also reported positive cash flow from operations, offsetting significant spending on its stock repurchase program. While facing ongoing litigation, the company's core business shows signs of strengthening, supported by product innovation and strategic segment focus.

TASER International, Inc. (now Axon Enterprise, Inc.) reported a significant improvement in financial performance for the first quarter of 2012 compared to the same period in 2011. Net sales increased by 10.9% to $25.6 million, primarily driven by strong adoption of the TASER X2 and increased sales of the X26 ECDs, including a significant order from the U.S. Army. The company also saw improved gross margins, rising to 59.4% from 52.8%, attributed to manufacturing efficiencies and a favorable product mix in the ECD segment. This operational improvement, combined with reduced litigation judgment expenses due to a favorable court ruling in the Turner case, led to a substantial increase in net income to $3.8 million ($0.07 per share) from a nominal $0.02 million ($0.00 per share) in the prior year. Cash flow from operations remained robust, providing $3.7 million, supporting a healthy cash balance of $29.7 million in cash, cash equivalents, and investments. The company also announced a new $20.0 million share repurchase program, signaling confidence in its financial position and future prospects. Despite ongoing litigation, the company appears to be navigating these challenges effectively, with a strong operational turnaround and positive financial outlook for the near term.

Axon Enterprise, Inc. (AXON), formerly TASER International, Inc., reported a net income of $1.14 million for the third quarter of 2011, a significant turnaround from a net loss of $2.34 million in the same period of the previous year. This improvement was driven by a 15.6% increase in net sales, reaching $24.4 million, primarily due to stronger domestic law enforcement sales and the introduction of the new TASER X2. Despite increased research and development expenses and a substantial litigation judgment expense, the company managed to improve its gross margin to 53.7% and reduce its SG&A expenses as a percentage of sales. For the first nine months of 2011, the company reported a net loss of $1.14 million, an improvement from a net loss of $4.19 million in the prior year period. Net sales grew by 7.3% to $68.7 million. The company generated positive cash flow from operations of $14.6 million, a notable shift from a negative $2.4 million in the prior year, supported by operational improvements and effective working capital management. However, a significant litigation judgment expense of $3.3 million and an asset impairment charge of $1.4 million impacted the year-to-date results.

Axon Enterprise, Inc. (AXON), formerly known as TASER International, Inc., reported its financial results for the quarter ended June 30, 2011. The company experienced a net sales increase of 10.9% to $21.2 million compared to the same period in the prior year, driven by strong international sales and the launch of the TASER X2. Despite the revenue growth, AXON reported a net loss of $2.3 million for the quarter, an increase from the $1.4 million net loss in Q2 2010. This widened loss was primarily due to a significant litigation judgment expense of $3.3 million related to an adverse jury verdict in the Turner v. TASER International case, and a $1.4 million asset impairment charge for the Protector product line. The company's gross margin improved considerably, rising to 57.8% from 50.4% year-over-year, indicating better cost management and a favorable product mix. Operationally, AXON saw a decrease in SG&A expenses as a percentage of sales, reflecting cost-cutting measures. However, research and development expenses also saw a reduction. The company maintained a strong liquidity position with $38.5 million in cash, cash equivalents, and investments as of June 30, 2011. AXON also continued its share repurchase program, investing $12.5 million in the quarter, and announced an additional $20 million repurchase authorization, signaling confidence in its financial stability despite the current period's net loss.

TASER International, Inc. (now Axon Enterprise, Inc.) reported a net income of $19,732 for the first quarter of 2011, a significant improvement from a net loss of $492,605 in the same period of 2010. This turnaround was driven by a 3% decrease in net sales to $23.1 million, coupled with a reduction in operating expenses, particularly in sales, general, and administrative (SG&A) and research and development (R&D). While overall sales declined slightly, the company saw positive contributions from new products like AXON/EVIDENCE.com and XREP. Financially, the company maintained a healthy liquidity position with $41.6 million in cash, cash equivalents, and investments as of March 31, 2011. Operating activities generated $4.3 million in cash, which, along with existing cash reserves, was sufficient to fund operations, strategic initiatives like a $12.5 million stock repurchase program, and capital expenditures. The company also reported no outstanding debt, with access to a $10 million line of credit.

Axon Enterprise, Inc. (AXON) reported a decrease in net sales for both the three-month and nine-month periods ending September 30, 2010, compared to the same periods in the prior year. The primary drivers for this decline were fewer individually significant international and federal orders, as well as constrained municipal spending due to challenging economic conditions. While overall sales decreased, the company is focusing on new product development, including its EVIDENCE.com platform, which is beginning to contribute to revenue. Despite the sales dip, the company has implemented cost-saving measures, leading to a reduction in Selling, General, and Administrative (SG&A) expenses. The company's gross margin also experienced a decline, impacted by a shift in product mix, increased costs associated with the EVIDENCE.com service, and higher indirect manufacturing expenses. Research and development expenses were significantly reduced, reflecting the completion of intensive development for certain new products in the prior year. Axon continues to maintain a strong balance sheet with ample cash and cash equivalents, and has access to a revolving credit facility, providing sufficient liquidity for its operations and strategic initiatives.

Axon Enterprise, Inc. (formerly TASER International, Inc.) reported a net loss of $1.85 million for the first six months of 2010, a widening from the $1.19 million loss in the same period of 2009. This was driven by a 7.5% decrease in net sales to $42.96 million, impacted by a significant drop in international orders and reduced sales of key products like the TASER X26 and single cartridges. Despite the revenue decline, the company saw some positive signs, including an increase in domestic sales in the first quarter of 2010, potentially linked to federal stimulus funding. The company is also investing in new product lines and technology, such as EVIDENCE.com, which contributed to a decrease in R&D expenses due to capitalization of software development costs. While the company's cash position decreased, it maintains a strong liquidity position with $40.6 million in cash and cash equivalents and an undrawn $10 million line of credit, suggesting it is adequately resourced to fund its operations and strategic initiatives.

TASER International, Inc. reported a net loss of $0.49 million for the first quarter ended March 31, 2010, a slight increase from the $0.47 million loss in the same period of 2009. Revenue also saw a marginal decline of 3.1% to $23.8 million. The company experienced a significant cash burn from operations, with $6.7 million used in the quarter compared to $10.5 million generated in the prior year's quarter, largely due to unfavorable changes in working capital, including an increase in inventory and a reduction in accounts payable. Despite the operational challenges, the company highlighted its strategic investments in new product development, including capitalized software development costs for EVIDENCE.com and the Protector Platform. The balance sheet shows a decrease in cash and cash equivalents to $37.4 million from $45.5 million at the end of 2009, while total assets decreased slightly to $135.9 million. The company maintains a strong liquidity position with $37.4 million in cash and an undrawn $10 million line of credit, and expects to renew this line of credit upon its maturity.

Axon Enterprise, Inc. (formerly TASER International, Inc.) reported net sales of $23.3 million for the third quarter of 2009, a modest 2.0% increase compared to the same period in 2008. This growth was primarily driven by an increase in federal business and international sales, which offset a decline in domestic municipal spending attributed to economic constraints. A new trade-in program for the TASER X26 ECD, offering an upgrade to the X3 ECD, deferred $3.5 million in revenue, impacting reported sales and gross margins. The company experienced a net loss of $3.2 million for the quarter, a significant decrease from the $0.65 million net income reported in Q3 2008, largely due to increased operating expenses, particularly in research and development and sales, general, and administrative categories, as the company invested in new product development and business infrastructure. For the first nine months of 2009, net sales increased by 5.0% to $69.7 million, again bolstered by international and federal sales, which countered weaker domestic demand. However, the company incurred a net loss of $4.4 million for this period, compared to a smaller net loss of $0.15 million in the prior year. This widened loss was primarily driven by substantial increases in R&D expenses related to new product development (TASER X3, AXON, EVIDENCE.com) and higher SG&A costs, including significant stock-based compensation expenses and costs associated with strategic initiatives. The company maintains a strong liquidity position with $45.4 million in cash and cash equivalents and an undrawn $10 million credit facility, indicating financial stability to fund operations and planned investments.